Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

The Smart Stop abstract examines the combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib in patients with newly diagnosed diffuse large B-cell lymphoma. Dr. Jason Westin discusses in this MEDtalk if targeted therapy can reduce or even eliminate the need for chemotherapy in these patients. Initial findings show a 63% complete response rate and a 100% overall response rate after four cycles of treatment.